New approaches to treating primary effusion lymphoma

Bibliography

• Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-9
   PubMed Web of Science ®Google Scholar
• Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003;21:3948-54
   PubMed Web of Science ®Google Scholar
• Knowles DM, Inghirami G, Ubriaco A, et al. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood 1989;73:792-9
   PubMed Web of Science ®Google Scholar
• Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-91
   PubMed Web of Science ®Google Scholar
• Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645-56
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-80
   PubMed Web of Science ®Google Scholar
• Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009;113:1213-24
   PubMed Web of Science ®Google Scholar
• Carbone A, Cesarman E, Gloghini A, et al. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS 2010;24:479-90
   PubMed Web of Science ®Google Scholar
• Goto H, Kojima Y, Nagai H, et al. Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma. Int J Hematol 2013;97:624-33
   Google Scholar
• Ansari MQ, Dawson DB, Nador R, et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 1996;105:221-9
   PubMed Web of Science ®Google Scholar
• Jones D, Ballestas ME, Kaye KM, et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998;339:444-9
   PubMed Web of Science ®Google Scholar
• Klepfish A, Sarid R, Shtalrid M, et al. Primary effusion lymphoma (PEL) in HIV-negative patients–a distinct clinical entity. Leuk Lymphoma 2001;41:439-43
   PubMed Web of Science ®Google Scholar
• Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003;17:1717-30
   PubMed Web of Science ®Google Scholar
• Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004;28:1401-16
   PubMed Web of Science ®Google Scholar
• Pan L, Milligan L, Michaeli J, et al. Polymerase chain reaction detection of Kaposi's sarcoma-associated herpesvirus-optimized protocols and their application to myeloma. J Mol Diagn 2001;3:32-8
   PubMed Web of Science ®Google Scholar
• Drexler HG, Meyer C, Gaidano G, et al. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines. Leukemia 1999;13:634-40
   PubMed Web of Science ®Google Scholar
• Michai M, Goto H, Hattori S, et al. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma. Asian Pac J Cancer Prev 2012;13:4939-41
   PubMedGoogle Scholar
• Friborg J Jr, Kong W, Hottiger MO, et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402:889-94
   PubMed Web of Science ®Google Scholar
• Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121-7
   PubMed Web of Science ®Google Scholar
• Swanton C, Mann DJ, Fleckenstein B, et al. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 1997;390:184-7
   PubMed Web of Science ®Google Scholar
• Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-21
   PubMed Web of Science ®Google Scholar
• Matta H, Chaudhary PM. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci USA 2004;101:9399-404
   PubMed Web of Science ®Google Scholar
• Kliche S, Nagel W, Kremmer E, et al. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol Cell 2001;7:833-43
   PubMed Web of Science ®Google Scholar
• McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 2005;307:739-41
   PubMed Web of Science ®Google Scholar
• Molden J, Chang Y, You Y, et al. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997;272:19625-31
   PubMed Web of Science ®Google Scholar
• Munoz-Fontela C, Marcos-Villar L, Hernandez F, et al. Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Virol 2008;82:1518-25
   PubMedGoogle Scholar
• Gao SJ, Boshoff C, Jayachandra S, et al. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997;15:1979-85
   PubMed Web of Science ®Google Scholar
• Gottwein E, Mukherjee N, Sachse C, et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007;450:1096-9
   PubMed Web of Science ®Google Scholar
• Skalsky RL, Samols MA, Plaisance KB, et al. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol 2007;81:12836-45
   PubMed Web of Science ®Google Scholar
• Matolcsy A, Nador RG, Cesarman E, et al. Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol 1998;153:1609-14
   PubMed Web of Science ®Google Scholar
• Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003;101:4115-21
   PubMed Web of Science ®Google Scholar
• Roy D, Sin SH, Damania B, et al. Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood 2011;118:e32-9
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Yao M, Hoshida Y, et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002;20:4255-60
   PubMed Web of Science ®Google Scholar
• Xiao J, Selvaggi SM, Leith CP, et al. Kaposi sarcoma herpesvirus/human herpesvirus-8-negative effusion-based lymphoma: report of 3 cases and review of the literature. Cancer Cytopathol 2013
   PubMedGoogle Scholar
• Alexanian S, Said J, Lones M, et al. KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol 2013;37:241-9
   PubMed Web of Science ®Google Scholar
• Chan AC, Chan JK, Yan KW, et al. Anaplastic large cell lymphoma presenting as a pleural effusion and mimicking primary effusion lymphoma. A report of 2 cases. Acta Cytol 2003;47:809-16
   PubMedGoogle Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372-80
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Shum H, Lahijani M, et al. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma 2012;53:2378-82
   PubMed Web of Science ®Google Scholar
• Boulanger E, Daniel MT, Agbalika F, et al. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003;73:143-8
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Clauvel JP, Jouveshomme S, et al. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol 1998;57:266
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Agbalika F, Oksenhendler E, et al. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001;15:280-2
   PubMed Web of Science ®Google Scholar
• Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004;104:2943-6
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84
   PubMed Web of Science ®Google Scholar
• Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96:2537-42
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16
   PubMed Web of Science ®Google Scholar
• Nikrad M, Johnson T, Puthalalath H, et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005;4:443-9
   PubMed Web of Science ®Google Scholar
• Boulanger E, Meignin V, Oksenhendler E. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol 2008;141:559-61
   PubMed Web of Science ®Google Scholar
• An J, Sun Y, Fisher M, et al. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18:1699-704
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59
   PubMed Web of Science ®Google Scholar
• Sarosiek KA, Cavallin LE, Bhatt S, et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA 2010;107:13069-74
   PubMed Web of Science ®Google Scholar
• Vaeteewoottacharn K, Kariya R, Matsuda K, et al. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma. J Cancer Res Clin Oncol 2013;139:1551-62
   PubMedGoogle Scholar
• Dabaghmanesh N, Matsubara A, Miyake A, et al. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci 2009;100:737-46
   PubMedGoogle Scholar
• Takahashi-Makise N, Suzu S, Hiyoshi M, et al. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer 2009;125:1464-72
   PubMed Web of Science ®Google Scholar
• Matsuno T, Kariya R, Yano S, et al. Diethyldithiocarbamate induces apoptosis in HHV-8-infected primary effusion lymphoma cells via inhibition of the NF-kappaB pathway. Int J Oncol 2012;40:1071-8
   PubMed Web of Science ®Google Scholar
• Goto H, Kariya R, Shimamoto M, et al. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-kappaB pathway. Cancer Sci 2012;103:775-81
   PubMedGoogle Scholar
• Gopalakrishnan R, Matta H, Chaudhary PM. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated Primary Effusion Lymphoma and blocks vFLIP K13-induced NF-kappaB. Clin Cancer Res 2013
   PubMedGoogle Scholar
• Nayar U, Lu P, Goldstein RL, et al. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood 2013
   PubMedGoogle Scholar
• Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42
   PubMed Web of Science ®Google Scholar
• Reed JC. The Survivin saga goes in vivo. J Clin Invest 2001;108:965-9
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005;24:7022-30
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Al-Hussein KA, et al. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005;11:3102-8
   PubMed Web of Science ®Google Scholar
• Tomlinson CC, Damania B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol 2004;78:1918-27
   PubMed Web of Science ®Google Scholar
• Wang L, Dittmer DP, Tomlinson CC, et al. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 2006;66:3658-66
   PubMed Web of Science ®Google Scholar
• Boulanger E, Marchio A, Hong SS, et al. Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma. Haematologica 2009;94:1170-4
   PubMed Web of Science ®Google Scholar
• Hussain AR, Ahmed M, Ahmed S, et al. Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. Free Radic Biol Med 2011;50:978-87
   PubMed Web of Science ®Google Scholar
• Hussain AR, Ahmed SO, Ahmed M, et al. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 2012;7:e39945
   PubMed Web of Science ®Google Scholar
• Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007;109:2165-73
   PubMed Web of Science ®Google Scholar
• Boulanger E, Afonso PV, Yahiaoui Y, et al. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008;8:707-10
   PubMed Web of Science ®Google Scholar
• Bayascas JR, Alessi DR. Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell 2005;18:143-5
   PubMedGoogle Scholar
• Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101
   PubMed Web of Science ®Google Scholar
• Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005;19:473-6
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Markovic SN, Kalokhe U, et al. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 2006;17:1849-50
   PubMed Web of Science ®Google Scholar
• Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6
   PubMed Web of Science ®Google Scholar
• Klass CM, Krug LT, Pozharskaya VP, et al. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005;105:4028-34
   PubMed Web of Science ®Google Scholar
• Fanger NA, Maliszewski CR, Schooley K, et al. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999;190:1155-64
   PubMed Web of Science ®Google Scholar
• Griffith TS, Wiley SR, Kubin MZ, et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-54
   PubMed Web of Science ®Google Scholar
• Toomey NL, Deyev VV, Wood C, et al. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 2001;20:7029-40
   PubMed Web of Science ®Google Scholar
• Wu W, Rochford R, Toomey L, et al. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk Res 2005;29:545-55
   PubMed Web of Science ®Google Scholar
• Lim ST, Rubin N, Said J, et al. Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab. Ann Hematol 2005;84:551-2
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
   PubMed Web of Science ®Google Scholar
• de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845-9
   PubMed Web of Science ®Google Scholar
• Bhatt S, Ashlock BM, Natkunam Y, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood 2013;122:1233-42
   PubMed Web of Science ®Google Scholar
• Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood 1999;94:4247-54
   PubMedGoogle Scholar
• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-802
   PubMed Web of Science ®Google Scholar
• Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003;21:4423-7
   PubMed Web of Science ®Google Scholar
• Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS 2004;18:67-73
   PubMed Web of Science ®Google Scholar
• Won JH, Han SH, Bae SB, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006;83:328-30
   PubMed Web of Science ®Google Scholar
• Goto H, Hagiwara S, Hirai R, et al. Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Rare Tumors 2011;3:e11
   Google Scholar
• Bryant A, Milliken S. Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant 2008;14:601-2
   PubMedGoogle Scholar
• Shiraishi Y, Gotoh K, Towata T, et al. Therapeutic effects of gamma-irradiation in a primary effusion lymphoma mouse model. Exp Ther Med 2010;79-84
   PubMedGoogle Scholar
• Cassoni A, Ali U, Cave J, et al. Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol 2008;26:5297-9
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Terunuma H, Toi M, et al. Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Sci 2006;97:1381-7
   PubMedGoogle Scholar
• Goto H, Matsuda K, Srikoon P, et al. Potent antitumor activity of zoledronic acid-induced Vgamma9Vdelta2 T cells against primary effusion lymphoma. Cancer Lett 2013;331:174-82
   PubMedGoogle Scholar
• Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004;22:2662-70
   PubMed Web of Science ®Google Scholar
• Combs S, Neil N, Aboulafia DM. Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study. Oncologist 2006;11:666-73
   PubMedGoogle Scholar
• Bi J, Espina BM, Tulpule A, et al. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 2001;28:416-21
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684-8
   PubMed Web of Science ®Google Scholar
• Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;37:1556-64
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-8
   PubMed Web of Science ®Google Scholar